Following the Eurostars grant in October, our portfolio company Avelo, a Swiss breath diagnostics start-up, has been awarded the next grant.
The CHF 1.5M Innosuisse Startup Innovation Project will be used to further develop a new breath sampling device called AveloCollect. The device is aimed at improving the diagnosis of lower respiratory tract infections (LRTIs), which are currently the fourth leading cause of death worldwide.
This 34-month project leverages Avelo’s ongoing Eurostars project and will focus on clinical development and market readiness for AveloCollect. This device’s compatibility with various respiratory pathogens positions this product as a potential game changer for roll-out in European markets and offers opportunities for global commercial partnerships.
More information in the press release under the following Link
More about Avelo
